Literature DB >> 22835870

Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

M Raymond V Finlay1, Roger J Griffin.   

Abstract

Modulation of DNA repair pathways in oncology has been an area of intense interest in the last decade, not least as a consequence of the promising clinical activity of poly(ADP-ribose) polymerase (PARP) inhibitors. In this review article, we highlight inhibitors of the phosphatidylinositol 3-kinase related kinase (PIKK) family as of potential interest in the treatment of cancer, both in combination with DNA-damaging therapies and as stand-alone agents.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22835870     DOI： 10.1016/j.bmcl.2012.06.053

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  10 in total

1.  Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.

Authors:  Hans-Richard Demel; Benedikt Feuerecker; Guido Piontek; Christof Seidl; Birgit Blechert; Anja Pickhard; Markus Essler
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.

Authors:  P O Carminati; F S Donaires; M M Marques; E A Donadi; G A S Passos; E T Sakamoto-Hojo
Journal:  Mol Biol Rep       Date:  2013-11-12       Impact factor: 2.316

3.  Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.

Authors:  Yuxia Cui; Stela S Palii; Cynthia L Innes; Richard S Paules
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.

Authors:  Carlos Rodrigo Gil del Alcazar; Molly Catherine Hardebeck; Bipasha Mukherjee; Nozomi Tomimatsu; Xiaohuan Gao; Jingsheng Yan; Xian-Jin Xie; Robert Bachoo; Li Li; Amyn A Habib; Sandeep Burma
Journal:  Clin Cancer Res       Date:  2013-12-23       Impact factor: 12.531

5.  Palladium(ii)-catalyzed synthesis of dibenzothiophene derivatives via the cleavage of carbon-sulfur and carbon-hydrogen bonds.

Authors:  Mamoru Tobisu; Yoshihiro Masuya; Katsuaki Baba; Naoto Chatani
Journal:  Chem Sci       Date:  2016-01-21       Impact factor: 9.825

6.  AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.

Authors:  Jacqueline H L Fok; Antonio Ramos-Montoya; Mercedes Vazquez-Chantada; Paul W G Wijnhoven; Valeria Follia; Neil James; Paul M Farrington; Ankur Karmokar; Sophie E Willis; Jonathan Cairns; Jenni Nikkilä; David Beattie; Gillian M Lamont; M Raymond V Finlay; Joanne Wilson; Aaron Smith; Lenka Oplustil O'Connor; Stephanie Ling; Stephen E Fawell; Mark J O'Connor; Simon J Hollingsworth; Emma Dean; Frederick W Goldberg; Barry R Davies; Elaine B Cadogan
Journal:  Nat Commun       Date:  2019-11-07       Impact factor: 17.694

Review 7.  Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining.

Authors:  Antonia Kefala Stavridi; Robert Appleby; Shikang Liang; Tom L Blundell; Amanda K Chaplin
Journal:  Essays Biochem       Date:  2020-10-26       Impact factor: 8.000

8.  DNA-dependent protein kinase is a context dependent regulator of Lmx1a and midbrain specification.

Authors:  Cameron P Hunt; Stewart A Fabb; Colin W Pouton; John M Haynes
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

9.  ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change.

Authors:  Marie-Hélène Montané; Benoît Menand
Journal:  J Exp Bot       Date:  2013-08-20       Impact factor: 6.992

Review 10.  Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Authors:  Hanley N Abramson
Journal:  Oncotarget       Date:  2016-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.